Compared with placebo, xanomeline/trospium as an add-on to atypical antipsychotics has not reached the threshold for a ...

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

This was a low-key week for the biotech sector before the onset of the first-quarter earnings season. Biotech giant Bristol Myers Squibb BMY was down on data from the schizophrenia study while ...

In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...

Bristol Myers Squibb’s schizophrenia drug Cobnefy failed to meet a primary goal in a phase 3 trial, possibly clouding the drug’s future development. The trial evaluated Cobnefy as an add-on therapy to ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy ...

Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...

Jefferies analyst Akash Tewari lowered the firm’s price target on Bristol Myers (BMY) to $68 from $70 and keeps a Buy rating on the shares ...

The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

US pharma major Bristol Myers Squibb (NYSE: BMY) saw its shares fall 4% in after-hours trading on Tuesday, after it announced ...